This inventor holds 3 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Immunocore Limited. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: Lucie Bouard: Innovator in Immunotherapy
Introduction
Lucie Bouard is a prominent inventor based in Abingdon, GB. She has made significant contributions to the field of immunotherapy, particularly through her work on T cell receptors. With a total of 3 patents to her name, her innovations are paving the way for new treatments in malignant diseases.
Latest Patents
Among her latest patents, Lucie has developed T cell receptors (TCRs) that specifically bind to the HLA-A*02 restricted peptide SLLQHLIGL, derived from the germline cancer antigen PRAME. These TCRs may include non-natural mutations within the alpha and/or beta variable domains compared to a native PRAME TCR. The TCRs she has invented are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant diseases.
Career Highlights
Lucie Bouard is currently associated with Immunocore Limited, where she continues to advance her research and innovations in immunotherapy. Her work is instrumental in developing new therapeutic strategies that could significantly impact cancer treatment.
Collaborations
Lucie collaborates with notable colleagues, including Philip William Addis and Nicole Joy Bedke, who contribute to her research endeavors and the advancement of their shared goals in the field of immunotherapy.
Conclusion
Lucie Bouard's innovative work in the development of T cell receptors represents a significant advancement in the fight against cancer. Her contributions are vital to the ongoing evolution of immunotherapeutic treatments.